![](https://investorshub.advfn.com/uicon/189332.png?cb=1465554763)
Monday, September 22, 2014 1:40:50 PM
If they haven't synthesized the material and haven't conducted tests, what results are they working on? The ones from ebolacide1 that were at best mildly effective? Really?
Yes,... really. It is a normal part of the process of science to publish results of tests, even if the results of those tests were not completely satisfactory.
In fact - Ebolacide I did 'work' fairly effectively in cell culture systems. The fact that it worked much less effectively in vivo reveals something about the nature of the virus, and how it interacts in a 'real' system.
So - yes - In Fact,.... they are claimed to be writing up the results of those old studies. The fact that the designed drug was not completely effective in vivo is still useful data for those who seek to understand how the system works as they might chose to build upon those findings.
Sometimes,.... more about how something works in science is revealed when the hypothesis being tested is not supported. A reassessment of the data,.... the discovery that the NCP1 gene may be the actual target that should have been aimed at since the Ebolacide I work was stopped led to the conceptualization of the new target to be used in Ebolacide II.
A simple understanding of how the process of science works is all it takes to understand this sequence - a series of questions, hypotheses, tests of hypotheses, and reassessment of them after experiments are conducted is the normal process. Often the results lead to re-designed questions and more hypotheses.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM